Small Pharma shares R&D update on the expansion of its DMT-based portfolio with deuterated DMT candidate and new clinical trials…
FDA schedules ODAC meeting for April 22, 2022NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today…
The Mixed Martial Artist, dubbed the Venezuelan Vixen, will collaborate to drive brand awareness as No BS expands omni-channel Julianna…
Dr. Hei has spent over two decades leading manufacturing teams at biotechnology companies and has deep expertise in the cell…
Patient dosing underway, interim efficacy data on track for second half 2022SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- TRACON…
●OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β●OT-101 has completed over six clinical trials against solid tumors with good efficacy●OT-101 is…
MONTREAL, March 10, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and…
Regulatory path forward supports company’s intention to initiate a planned registrational study in the third quarter of 2022.SAN DIEGO, March…
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF…
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing…